Source link : https://newshealth.biz/health-news/new-standard-of-care-in-rare-deadly-blood-cancer/
CHICAGO — The antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) yielded high response rates with good durability in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in the phase 1/2 CADENZA trial. “We conclude that PVEK represents a potentially practice-changing paradigm for patients with the rare disease BPDCN,” said study author Naveen Pemmaraju, MD, of MD […]
The post New Standard of Care in Rare, Deadly Blood Cancer? first appeared on News Health.
—-
Author : News Health
Publish date : 2025-06-05 12:09:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8